Shrunk NSAIDs market led by domestic drugs

Published: 2016-02-04 16:25:59

Updated: 2016-02-04 16:25:59

The domestic osteoarthritis treatment market led by Pfizer Pharmaceuticals Korea’s ‘Celebrex’ has quickly been depressed.

The patent expiration of the leading product, Celebrex, and the increased prescriptions of NSAIDs+PPI complexes were analyzed as the main causes of the phenomenon.

According to the analysis result of the past 4 years’ outpatient prescriptions of the top 5 NSAIDs-type subst...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.